金黄色葡萄球菌耐药性早期治疗与重复试验 (STAR-TER)
STAR-TER 是一项针对囊性纤维化（CF）患者新发 MRSA 呼吸道感染的开放标签、多中心干预试验，计划入组 42 名受试者
基本信息
资源简介
金黄色葡萄球菌耐药性早期治疗与重复试验 (STAR-TER)
STAR-TER 是一项针对囊性纤维化（CF）患者新发 MRSA 呼吸道感染的开放标签、多中心干预试验，计划入组 42 名受试者。受试者将接受为期 14 天的口服 trimethoprim-sulfamethoxazole (TMP-SMX) 或 minocycline（依据年龄、过敏史及既往分离株耐药情况选择），并接受 5 天鼻用 mupirocin；年龄足够的受试者还将使用 0.12% chlorhexidine gluconate 口腔漱口水 14 天。主要终点为第 28 天 MRSA 呼吸道培养阳性比例，并与既往 STAR-Too 结果比较。该数据可用于评估联合抗菌策略对 MRSA 清除的效果及预测治疗应答（来源 clini。
【数据内容】
源站描述（机器翻译，仅供参考）：条件：囊性纤维化。这是一项开放标签、多中心干预试验，对象为在临床就诊时从呼吸道（口咽（OP）= OP 拭子、痰液或支气管镜）新分离出 MRSA 的囊性纤维化（CF）患者。将入组 42 名新发 MRSA 感染受试者，根据年龄、过敏史和既往分离株的抗生素耐药性，接受为期 14 天的口服 trimethoprim-sulfamethoxazole (TMP-SMX) 或 minocycline，以及 5 天的鼻用 mupirocin。年龄足够大的受试者将使用口服消毒漱口水（0.12% chlorhexidine gluconate 口腔冲洗液）14 天。主要终点是第 28 天 MRSA 呼吸道培养阳性的比例，并将与既往 STAR-Too 结果进行比较。随后受试者将经历 14 天的洗脱期（即第 14 天至第 28 天不使用 TMP-SMX 或 minocycline），所有受试者……
【主题与分类】
主题标签：Cystic Fibrosis。本站分类：呼吸系统疾病/其他。
【获取与许可】
源站页面：https://clinicaltrials.gov/study/NCT03489629
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站：https://clinicaltrials.gov/study/NCT03489629
标准获取流程：
- 访问源站链接，注册/登录账号；
- 进入数据集详情页，按页面指引申请权限或直接下载；
- 部分平台提供 SDK，例如：
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Cystic Fibrosis. This is an open-label, multi-center interventional trial in Cystic Fibrosis (CF) patients with new MRSA isolated from the respiratory tract (oropharyngeal (OP) = OP swab, sputum, or bronchoscopy) at a clinical encounter. Forty-two subjects with new MRSA infection will be enrolled and will receive two weeks of oral trimethoprim-sulfamethoxazole (TMP-SMX) or minocycline depending on age, allergies and antibiotic resistance of prior isolate for 14 days, and nasal mupirocin for 5 days. Subjects old enough to do so will use oral disinfectant gurgle (0.12% chlorhexidine gluconate oral rinse) for 14 days. The primary endpoint will be the proportion of positive MRSA respiratory cultures at Day 28 and this will be compared to our prior STAR-Too results. Subjects will then have a 14 day wash-out period (i.e., no TMP-SMX or minocycline from Day 14 to Day 28) and all participants will repeat the treatment protocol from Day 29 to Day 42. Repeat cultures will be done at day 56 ± 7 days, most likely combined with their next clinic visit. Results of Day 56 cultures will be an exploratory, secondary outcome. A subsequent visit will be 3 months later with their routine clinic appointment. Any interim clinic visits will be used to obtain repeat cultures and clinical data. Assessment of MRSA culture status will be by OP swab for all subjects, with additional sputum in those who expectorate. Total duration of an individual subject’s participation will be six months. Total duration of the study is expected to be 42 months, which includes data analyses and publication. Due to COVID 19 restrictions, a study amendment was filed in March 2020 for subjects currently active subjects that allowed remote study visit for V3 and V4. Cultures were collected at home and mailed to the Core Study lab, clinical case forms and surveys were completed via video visits. These changes were approved by each study site that this was relevant to i.e. 4 study sites had subjects active at that time.
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
需要用于商业化训练或医疗器械注册（NMPA/FDA）？
公开数据往往缺乏完整的病理回证与专家标注。千方医数集依托陕川双基地与超十家三甲医院直连，提供完全合规、去标识化、支持注册级质控的专病数据集交易服务。
